麥科醫藥－Ｂ 02335Stock Information

Stock Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
// Company Overview //
Stock Name麥科醫藥－Ｂ
Stock Code02335
Company Full Name麥科醫藥－Ｂ
Industry生物医药
Principal Activities專注於發現、開發及商業化雙╱多特異性肽類藥物，用於治療代謝性疾病以及心腦血管疾病，核心產品處於III期臨床試驗
Listing Date2026-06-24
Listing Rules Era
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國陝西省西安市長安區協同創新港6號樓
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座31樓
Place of Incorporation中国
Listing Method全球发售
Listing BoardMain Board
Websitemicrotechmd.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar ContactNo data
A-Share/US Dual ListingNo
// Offering Information //
Offering Mechanism 机制B
Clawback Tiers机制B不设回拨，公开发售占比维持10.0%
Offer Period2026-06-15 to 2026-06-18
Offer PriceHK$ 18.20 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,640
Par ValueRMB 0.02 / shares
Global Offering Shares58,054,400
HK Public Offering Shares5,805,600 (10.0%)
International Placing Shares52,248,800 (90.0%)
Offer RatioNo data
Total Shares Post-IPO331,740,350 shares
Total Global Offering SizeHK$ 1,056,590,080
Public Offering SizeHK$ 105,661,920 (10.0%)
Oversubscription Multiple1,032.9x
Valid Applications153,832
Accepted Applications22,665
ReallocationNo
Greenshoe (Over-allotment Option)No
Final Public Offering Share10.0%
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 6,502,110,860
Pre-IPO Valuation (Last Round)No data
P/E Ratio不適用（公司處於虧損狀態）
Profit/Loss Status虧損約人民幣184.9百萬元
Period-End Cash BalanceNo data
Listing Expenses~HK$ 70,550,000
Listing Expenses / Funds RaisedNo data
Total Pre-IPO InvestmentNo data
// First Day Performance
First Day CloseLoading...
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds約39.1%用於核心產品臨床試驗及商業化，36.3%用於關鍵產品臨床試驗及商業化，14.6%用於其他候選產品及技術平台研發，10.0%用於營運資金及一般公司用途
// Underwriting Syndicate //
联席保荐人 (1)
建银国际金融有限公司
保荐人兼整体协调人 (1)
建银国际金融有限公司
整体协调人 (1)
建银国际金融有限公司
联席全球协调人 (2)
建银国际金融有限公司 招商证券（香港）有限公司
联席账簿管理人 (12)
建银国际金融有限公司 招商证券（香港）有限公司 嘉高达证券集团有限公司 瑞邦证券有限公司 国金证券（香港）有限公司 天泽证券有限公司 新百利融资有限公司 老虎证券（香港）环球有限公司 盈立证券有限公司 微牛证券有限公司 中泰国际证券有限公司 中募金融资管有限公司
联席牵头经办人 (12)
建银国际金融有限公司 招商证券（香港）有限公司 嘉高达证券集团有限公司 瑞邦证券有限公司 国金证券（香港）有限公司 天泽证券有限公司 新百利融资有限公司 老虎证券（香港）环球有限公司 盈立证券有限公司 微牛证券有限公司 中泰国际证券有限公司 中募金融资管有限公司
资本市场中介人 (12)
建银国际金融有限公司 招商证券（香港）有限公司 嘉高达证券集团有限公司 瑞邦证券有限公司 国金证券（香港）有限公司 天泽证券有限公司 新百利融资有限公司 老虎证券（香港）环球有限公司 盈立证券有限公司 微牛证券有限公司 中泰国际证券有限公司 中募金融资管有限公司
// Service Providers //
RoleInstitution
本公司法律顾问 天元律师事务所
君合律师事务所
King and Wood LLP
天元律师事务所
国浩律师（深圳）事务所
Concord & Sage PC
保荐人/包销商法律顾问 周俊轩律师事务所
通商律师事务所
核数师兼申报会计师 德勤•关黄陈方会计师行
行业顾问 弗若斯特沙利文（北京）咨询有限公司上海分公司
收款银行 招商永隆银行有限公司
// Cornerstone Investors // Allotment Results Announcement
#Investor NameShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 王冰博士 111,000,000 23.78% 33.46% 2027-06-23 2027-06-23
2 蘇州麥紐 27,333,350 9.76% 8.24% 2027-06-23 2027-06-23
3 啟源香港 18,756,200 6.70% 5.65% 2026-12-23 2026-12-23
4 王梅博士 18,060,050 6.45% 5.44% 2027-06-23 2027-06-23
5 越焯 17,733,350 6.33% 5.35% 2027-06-23 2027-06-23
6 西安眾瑞 15,000,000 5.36% 4.52% 2027-06-23 2027-06-23
7 臨海啟澤 14,382,650 5.14% 4.34% 2027-06-23 2027-06-23
8 華新醫藥創投 7,776,650 2.78% 2.34% 2027-06-23 2027-06-23
9 蘇州融晟 6,833,350 2.44% 2.06% 2027-06-23 2027-06-23
10 新材料基金 6,000,000 2.14% 1.81% 2027-06-23 2027-06-23
11 西安同尚 5,939,950 2.12% 1.79% 2027-06-23 2027-06-23
12 雲頂新耀 5,494,400 1.96% 1.66% 2026-12-23 2026-12-23
13 豐川弘博 5,125,000 1.83% 1.54% 2027-06-23 2027-06-23
14 精誠大興 5,075,100 1.81% 1.53% 2027-06-23 2027-06-23
15 唐興科創 4,780,200 1.71% 1.44% 2027-06-23 2027-06-23
16 君盈成長 3,982,350 1.42% 1.20% 2027-06-23 2027-06-23
17 善金閏濟 3,947,750 1.41% 1.19% 2027-06-23 2027-06-23
18 上市後備基金 3,631,750 1.30% 1.09% 2027-06-23 2027-06-23
19 君盈佳成 2,017,650 0.72% 0.61% 2027-06-23 2027-06-23
20 麥誠世紀 1,557,700 0.56% 0.47% 2027-06-23 2027-06-23
21 海南萬風 1,361,900 0.49% 0.41% 2027-06-23 2027-06-23
22 濟南六驥 1,246,150 0.44% 0.38% 2027-06-23 2027-06-23
23 西安匯譽 907,950 0.32% 0.27% 2027-06-23 2027-06-23
24 隱雲合曼 907,950 0.32% 0.27% 2027-06-23 2027-06-23
25 杭州全德旺 907,950 0.32% 0.27% 2027-06-23 2027-06-23
26 海南瑞正 907,950 0.32% 0.27% 2027-06-23 2027-06-23
27 順鳴資本 430,400 0.74% 0.13% 2026-12-23 2026-12-23
// Directors & Management //
Chairman王冰
Company Secretary鄒然、陳綺藍
No director data available.
// Major Shareholders //
Major Shareholders & Holdings王冰博士及王梅博士為控股股東，合共持有本公司約43.43%權益（假設超額配股權未獲行使）
// Allotment Benchmarks //
Pool A (Small Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
200 44,060 1,322 0.03
400 24,701 976 0.04
600 4,048 188 0.05
800 2,703 141 0.05
1,000 3,083 175 0.06
1,200 1,918 118 0.06
1,400 1,344 88 0.07
1,600 1,425 98 0.07
1,800 1,500 108 0.07
2,000 12,982 970 0.07
3,000 3,436 302 0.09
4,000 4,863 479 0.10
5,000 1,990 214 0.11
6,000 1,481 171 0.11
7,000 1,130 139 0.12
8,000 1,070 139 0.13
9,000 1,558 212 0.14
10,000 6,201 877 0.14
20,000 5,421 1,009 0.19
30,000 3,691 807 0.23
40,000 2,469 605 0.24
50,000 1,567 420 0.28
60,000 1,352 389 0.30
70,000 1,071 328 0.32
80,000 750 242 0.32
90,000 647 219 0.36
100,000 4,429 1,559 0.35
200,000 479 2,219 0.50
Pool B (Large Subscriptions)
Shares AppliedApplicantsAllotteesExpected Lots
300,000 4,433 2,217 1.50
400,000 912 609 1.60
500,000 725 588 1.75
600,000 348 326 1.80
700,000 339 339 2.10
800,000 204 32 2.00
900,000 123 31 2.25
1,000,000 618 209 2.50
2,000,000 126 126 3.00
2,902,800 323 169 2.90
Offer Ratio
Allotment Benchmarks
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics